<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of Charlson comorbidity index (CCI) and hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of Charlson comorbidity index (CCI) and hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of Charlson comorbidity index (CCI) and hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="30%"></colgroup><colgroup width="10%"></colgroup><colgroup width="30%"></colgroup><colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1">Comorbidity</td> <td class="subtitle1">Charlson comorbidity index (CCI) definition</td> <td class="subtitle1">CCI score</td> <td class="subtitle1">Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) definition</td> <td class="subtitle1">HCT-CI score</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Pulmonary disease</td> </tr> <tr> <td class="indent1">Mild</td> <td>Dyspnea on moderate activity (or with asthma attacks)</td> <td>1</td> <td>Dyspnea on moderate activity or DLCO and/or FEV<sub>1</sub> 81 to 90%</td> <td>0</td> </tr> <tr> <td class="indent1">Moderate</td> <td>Dyspnea on slight activity</td> <td>1</td> <td>Dyspnea on slight activity or DLCO and/or FEV<sub>1</sub> 66 to 80%</td> <td>2</td> </tr> <tr> <td class="indent1">Severe</td> <td>Dyspnea at rest or requires oxygen</td> <td>1</td> <td>Dyspnea at rest or requires oxygen or DLCO and/or FEV<sub>1</sub> ≤65%</td> <td>3</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Cardiac disease</td> </tr> <tr> <td class="indent1">General</td> <td>Congestive heart failure (symptomatic and requiring treatment) and myocardial infarction were included as independent comorbidities, each acquiring a score of 1</td> <td>1 or 2</td> <td>Coronary artery disease*, congestive heart failure, myocardial infarction, or EF ≤50%</td> <td>1</td> </tr> <tr> <td class="indent1">Arrhythmia</td> <td>N/A</td> <td>0</td> <td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td> <td>1</td> </tr> <tr> <td class="indent1">Heart valve disease</td> <td>Except mitral valve prolapse</td> <td>0</td> <td>Except mitral valve prolapse</td> <td>3</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Hepatic disease</td> </tr> <tr> <td class="indent1">Mild</td> <td>Chronic hepatitis or cirrhosis</td> <td>1</td> <td>Chronic hepatitis, bilirubin &gt;ULN to 1.5 × ULN, or AST/ALT &gt;ULN to 2.5 × ULN</td> <td>1</td> </tr> <tr> <td class="indent1">Moderate to severe</td> <td>Cirrhosis with portal hypertension ± bleeding varices</td> <td>3</td> <td>Cirrhosis or fibrosis or bilirubin &gt;1.5 × ULN or AST/ALT &gt;2.5 × ULN</td> <td>3</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Renal disease</td> </tr> <tr> <td class="indent1">Mild</td> <td>Serum creatinine 2 to 3 mg/dL</td> <td>0</td> <td>Creatinine 1.2 to 2 mg/dL</td> <td>0</td> </tr> <tr> <td class="indent1">Moderate to severe</td> <td>Creatinine &gt;3 mg/dL, renal dialysis, or renal transplant</td> <td>2</td> <td>Creatinine &gt;2 mg/dL, renal dialysis, or renal transplant</td> <td>2</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Other malignancies</td> </tr> <tr> <td class="indent1">Prior solid tumor</td> <td>Initially treated in the last 5 years</td> <td>2</td> <td>Treated at any time point in the patient's history, excluding nonmelanoma skin cancer</td> <td>3</td> </tr> <tr> <td class="indent1">Metastatic cancer</td> <td>Present</td> <td>6</td> <td>Not included</td> <td>N/A</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Other comorbidities</td> </tr> <tr> <td class="indent1">Diabetes</td> <td>Requiring treatment with insulin or oral hypoglycemics but not diet alone</td> <td>1</td> <td>Requiring treatment with insulin or oral hypoglycemics but not diet alone</td> <td>1</td> </tr> <tr> <td class="indent1">Cerebrovascular disease</td> <td>Transient ischemic attack or cerebrovascular accident</td> <td>1</td> <td>Transient ischemic attack or cerebrovascular accident</td> <td>1</td> </tr> <tr> <td class="indent1">Rheumatologic</td> <td>SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica</td> <td>1</td> <td>SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica</td> <td>2</td> </tr> <tr> <td class="indent1">Peptic ulcer</td> <td>Requiring treatment</td> <td>1</td> <td>Requiring treatment</td> <td>2</td> </tr> <tr> <td class="indent1">Psychiatric disturbance</td> <td>Not included</td> <td>N/A</td> <td>Depression or anxiety requiring psychiatric consult or treatment</td> <td>1</td> </tr> <tr> <td class="indent1">Infection</td> <td>Not included</td> <td>N/A</td> <td>Requiring continuation of antimicrobial treatment after day 0</td> <td>1</td> </tr> <tr> <td class="indent1">Inflammatory bowel disease</td> <td>Not included</td> <td>N/A</td> <td>Crohn disease or ulcerative colitis</td> <td>1</td> </tr> <tr> <td class="indent1">Obesity</td> <td>Not included</td> <td>N/A</td> <td>Patients with a body mass index &gt;35 kg/m<sup>2</sup></td> <td>1</td> </tr> </tbody></table></div><div class="graphic_lgnd">To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.</div><div class="graphic_footnotes"><p>DLCO: diffusion capacity of carbon monoxide; FEV<sub>1</sub>: forced expiratory volume in one second; EF: ejection fraction; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; CTD: connective tissue disease.</p>
* One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.</div><div class="graphic_reference">Data from: Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.</div><div id="graphicVersion">Graphic 59272 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
